Rongshi Li, Ph.D.


Chemistry and Medicinal Chemistry
Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986805 Nebraska Medical Center
Omaha, NE 68198-6805
402-559-6609 (Office)
402-559-6521 (Lab)
402-559-5418 (Fax)

Teaching Activities:

Pharmaceutical Biotechnology PHSC 520 (course coordinator)

Medicinal Chemistry I PHSC 626

Medicinal Chemistry II PHSC 628

Pharmaceutical Sciences Applications in Pharmacy PHSC 691


Research Activities/Interests:

Fragment-based and structure-guided design of enzyme inhibitors and disruptors of protein-protein interactions; synthesis of natural products and their derivatives for drug discovery; hit-to-lead and lead optimization using organic/medicinal chemistry; drug design and development in anti-cancer and anti-infective therapeutics.


Recent Publications:

  1. Li, R.*; Cheng, C.; Balasis, M.E.; Liu, Y.; Garner, T.P.; Daniel, K.G.; Li, J.; Qin, Y.; Gavathiotis, E.; Sebti, S.M. Design, Synthesis and Evaluation of Marinopyrrole Derivatives as Selective Inhibitors of Mcl-1 Binding to Pro-apoptotic Bim and Dual Mcl-1/Bcl-xL Inhibitors. Eur. J. Med. Chem. In press.
  2. Smith, E.W.; Liu, Y.; Getschman, A.E.; Peterson, F.C.; Ziarek, J.J.; Li, R.*; Volkman, B.F.; Chen, Y. Structural Analysis of a Novel Small Molecule Ligand Bound to the CXCL12 Chemokine. J. Med. Chem. 2014, Epub ahead of print (October 30, 2014). Pubmedid: 25356720.
  3. Cheng, C.; Liu, Y.; Balasis, M.E.; Simmons, N.L.; Li, J.; Song, H.; Pan, L.; Qin, Y.; Nicolaou, K.C.; Sebti, S.M.; Li, R.* Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-xL Binding to Bim. Mar. Drugs 2014, 12, 1335–1348. Pubmedid: 24608970.
  4. Patel, R.A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S.M. Identification of Novel ROCK Inhibitors with Anti-migratory and Anti-invasive Activities. Oncogene, 2014, 33, 550–555(a featured articleon 23396364.
  5. Liu, Y.; Haste, N.M.; Thienphrapa, W.; Li, J.; Nizet, V.; Hensler, M.; Li, R.* Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (III). Mar. Drugs 2014, 12, 2458–2470. Pubmedid: 24796304.
  6. Ziarek, J.J.; Liu, Y.; Smith, E.; Zhang, G.; Peterson, F.C.; Chen, J.; Yu, Y.; Chen, Y. Volkman, B.F.; Li, R.* Fragment-based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction. Curr. Top. Med. Chem. 2012, 12, 2727–2740. Pubmedid: 23368099.
  7. Li, R.*; Martin, M.P.; Liu, Y.; Wang, B.; Patel, R.A.; Sun, N.; Pireddu, R.; Lawrence, N.J.; Li, J.; Haura, E.B.; Sung, S.S.; Guida, W.C.; Schonbrunn, E.; Sebti, S.M. Fragment-based and Structure-guided Discovery and Optimization of Rho Kinase Inhibitors. J. Med. Chem. 2012, 55, 2474–2478. Pubmedid: 22272748.
  8. Cheng, C.; Pan, L.; Chen, Y.; Song, H.; Qin, Y.; Li, R.* Total Synthesis of (±)-Marinopyrrole A and Its Library as Potential Antibiotic and Anti-cancer Agents. J. Comb. Chem. 2010, 12, 541–547. Pubmedid: 20429575.
  9. Li, R.*; Pourpak, A.; Morris, S.W. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach. J. Med. Chem. 2009, 52, 4981–5004. (One of 10 Most-Accessed Articles, July-Sept. 2009). Pubmedid: 19610618.
  10. Li, R.*; Morris, S.W. Development of Anaplastic Lymphoma Kinase (ALK) Small-Molecule Inhibitors for Cancer Therapy. Med. Res. Rev. 2008, 28, 372–412. Pubmedid: 17694547.


Rongshi Li, Ph.D.
Dr. Li